Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma
Authors:
- Chengcheng YanCYChengcheng Yan
- Melissa A. RichardMRMelissa A. Richard
- Christopher J. GibsonCGChristopher J. Gibson
- Alysia BosworthABAlysia Bosworth
- David K. CrossmanDCDavid K. Crossman
- Purnima SinghPSPurnima Singh
- Saro H. ArmenianSASaro H. Armenian
- Julie VoseJVJulie Vose
- Daniel J. WeisdorfDWDaniel J. Weisdorf
- 10 July 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (20) , 2415-2424
Abstract
PURPOSE: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS: We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71). Targeted DNA sequencing of PBSC products performed for CH-associated or myeloid malignancy-associated genes identified pathogenic mutations in these patients. RESULTS: CH was identified in the PBSC product of 46 patients (14.3%) with most prominent representation of DNMT3A (n = 25), PPM1D (n = 7), TET2 (n = 7), and TP53 (n = 5) mutations. Presence of CH in the PBSC product was an independent predictor of t-MN (adjusted hazard ratio [aHR], 4.50 [95% CI, 1.54 to 13.19]). Notably all patients with TP53 mutations in the PBSC product developed t-MN, whereas none of the patients with DNMT3A mutations alone (without co-occurring TP53 or PPM1D mutations) did. Presence of TP53 and/or PPM1D mutations was associated with a 7.29-fold higher hazard of t-MN when compared with individuals carrying no CH mutations (95% CI, 1.72 to 30.94). The presence of TP53 and/or PPM1D mutations was also associated with a 4.17-fold higher hazard of nonrelapse mortality (95% CI, 1.25 to 13.87). There was no association between CH and relapse-related mortality. CONCLUSION: The presence of TP53 and/or PPM1D mutations in the PBSC product increases the risk of post-aPBSCT t-MN and nonrelapse mortality among patients with HL and may support alternative therapeutic strategies.Keywords
This publication has 25 references indexed in Scilit:
- Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort studyLeukemia, 2020
- PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic ChemotherapyCell Stem Cell, 2018
- Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCell Stem Cell, 2017
- Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyThe Lancet Oncology, 2017
- Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control studyThe Lancet Oncology, 2017
- Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseasesLeukemia Research, 2015
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014
- Age-related mutations associated with clonal hematopoietic expansion and malignanciesNature Medicine, 2014
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemiaNature, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013